HUB Organoids
Business Services · Netherlands · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Yalelaan 62, Utrecht, Utrecht, 3582, Net...Phone Number
+31 881236300Website
www.huborganoids.nlRevenue
$15.7 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
1
1
1
1
About HUB Organoids
HUB Organoids specializes in patient-derived organoids for drug discovery and organoid development services. Their patented technology creates 'mini-organs in a dish' from both healthy and diseased tissues, enabling the prediction of patient responses to treatments. They offer preclinical services, custom model and assay development, and a licensing program for their technology. Their therapeutic focus includes oncology, immuno-oncology, inflammatory diseases, genetic diseases, infectious diseases, and toxicology.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is HUB Organoids your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when HUB Organoids launches new products
Funding: Get notified immidiatlly once HUB Organoids has new funding data
HUB Organoids, which may be a good buyer, showed buying intent in Masked Content Topic
Check if HUB Organoids has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at HUB Organoids
Earning: See what the market has to say on HUB Organoids recently announced quarterly report
Click to see if HUB Organoids had a recent Job posting/layoffs
Check out if HUB Organoids is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined HUB Organoids as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
HUB Organoids is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
HUB Organoids is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about HUB Organoids.
HUB Organoids Tech Stack
A closer look at the technologies used by HUB Organoids
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Award
Award
HUB Organoids News & Media
HUB Organoids B.V. Awarded Frost & Sullivan's 2024 Technology Innovation Leadership Award for Transforming Drug Development with Highly Advanced Organoid Technology
HUB Organoids Holdings B.V. revolutionizes pre-clinical and clinical drug development through its cutting-edge organoid technology, enhancing its accuracy and efficiency. SAN ANTONIO, May 14, 2024 /PRNewswire/ -- Frost & Sullivan recently researched the organoids landscape and, based on its findings, recognizes HUB Organoids B.V (HUB) with the 2024 Global Technology Innovation Leadership Award. HUB is a global leader in patient-derived organoid (PDO) technology that enables drug developers to idMolecular Devices inks deal with HUB Organoids to advance automated...
Molecular Devices and HUB Organoids collaborate to enable continued development of next-generation 3D biology technologies that drive step-change reduction in pre-clinical to clinical drug attrition. (PRWeb February 13, 2023) Read the full story at https://www.prweb.com/releases/2023/2/prweb19165481.htmCrown Bioscience: First Clinical Candidate Developed Using HUB Organoids® and High Content Screening Targets Cancer Stem Cells in Solid Tumors, Published in Nature Cancer
SAN DIEGO--(BUSINESS WIRE)--Crown Bioscience, a JSR Life Sciences company, and HUB Organoids (HUB) announced today the publication of preclinical data in the journal, Nature Cancer, on a bispecific antibody which prevents the onset of metastasis and slows the growth of primary tumors in experimental models of cancer. The study was the result of work by an international consortium, SuppresSTEM which included Crown Bioscience (previously OcellO B.V.) and HUB. Crown Bioscience and HUB led the desi
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding HUB Organoids
Sign Up For FreeTo access detailed company insights
HUB Organoids specializes in patient-derived organoids for drug discovery and organoid development services. Their patented technology creates 'mini-organs in a dish' from both healthy and diseased tissues, enabling the prediction of patient responses to treatments. They offer preclinical services, custom model and assay development, and a licensin... Read More
